Drug shortages: Searching for a cure

Healthcare Policy

Volumn 7, Issue 4, 2012, Pages 10-17

  Gagnon, Marc André ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GENERIC DRUG; LABETALOL; OSELTAMIVIR;

CANADA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG STORAGE; HEALTH SERVICE; PRESCRIPTION; QUALITY CONTROL; REVIEW;

CANADA; DRUG INDUSTRY; DRUGS, GENERIC; FINANCING, GOVERNMENT; HUMANS; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84861470162     PISSN: None     EISSN: 17156572     Source Type: Journal    
DOI: 10.12927/hcpol.2012.22887     Document Type: Review

References (18)

1. Beerten, E. and F. Bonheure. 2011 (November 15). "Autour du monde - des indisponibilités de médicaments."Annales Pharmaceutiques Belges: 11-14.
2. Canadian Pharmacists Association. 2010 (December). Canadian Drug Shortages Survey: Final Report. Ottawa: Author.
3. Cherici, C., P. McGinnis and W. Russell. 2011. "Buyer Beware: Drug Shortages and the Gray Market." Premier Healthcare Alliance report. Retrieved April 18, 2012. 〈https://www.premierinc.com/about/news/11-aug/ Gray- Market/Gray-Market-Analysis-08152011.pdf〉.
4. Doshi, P. and T. Jefferson. 2012 (April 10). "Drug Data Shouldn't Be Secret." The New York Times. Retrieved April 18, 2012. 〈http://www.nytimes.com/2012/04/11/opinion/drug-data-shouldnt-be-secret. html〉.
5. Gardner, A. 2008 (April 23). "Researchers Identify Contaminant in Tainted Heparin." The Washington Post. Retrieved April 18, 2012. 〈http://www.washingtonpost.com/wp-dyn/content/article/2008/04/23/ AR2008042302836.html〉.
6. Gray, A. and H.R. Manasse. 2012. "Shortages of Medicines: A Complex Global Challenge." Bulletin of the World Health Organization 90: 158-158A.
7. Harding, D. 2010 (December). "Gaining Market Share in the Generic Drug Industry through Acquisitions and Partnerships." Thomson Reuters. Retrieved April 18, 2012. 〈http://thomsonreuters.com/content/science/pdf/ ls/ newport-deals.pdf〉.
8. Havrankova, J. 2012 (March 21). "Pharma-Québec: Une urgence." Retrieved April 18, 2012. 〈http://www.professionsante. ca/medecins/opinions/blogues/de-la-sante-et-dautres-sujets/pharma-quebec-une- urgence-2-17411〉
9. IMS Institute for Healthcare Informatics. 2011 (May). The Global Use of Medicines: Outlook through 2015. Parsippany, NJ: Author.
10. Institute for Safe Medication Practices Canada. 2012 (March 20). "Drug Shortages and Medication Safety Concerns." ISMP Canada Safety Drug Bulletin 12(3).
11. Jack, A. and A. Rappeport. 2011 (September 27). "Generic Drugs Group Warns Over US Regulation." The Financial Times. Retrieved April 18, 2012. 〈http://www.ft.com/cms/s/0/78b7ee8a-e921-11e0-9817-00144feab49a. html#axzz1sQWC1fXs〉.
12. Koh, H. 2011 (September). "Examining the Increase in Drug Shortages." Statement before the Committee on Energy and Commerce, Subcommittee on Health, United States House of Representatives. Retrieved April 18, 2012. 〈http://www.hhs.gov/asl/testify/2011/09/t20110923a.html〉.
13. McKie, D. 2011 (May 24). "Tamiflu Marketing Exposes Holes in Drug Regulatory Regime." CBC News. Retrieved April 18, 2012. 〈http://www.cbc.ca/news/politics/inside-politics-blog/2011/05/ tamiflu-marketing-exposesholes- in-drug-regulatory-regime.html〉.
14. Moïse, P. and E. Docteur. 2007. Pharmaceutical Pricing and Reimbursement Policies in Sweden. OECD Health Working Papers #28. Retrieved April 18, 2012. 〈http://www.oecd.org/dataoecd/63/17/40699881.pdf〉.
15. Morrison, A. 2011 (March). "Drug Supply Disruptions." Environmental Scan 17. Ottawa: Canadian Agency for Drugs and Technologies in Health. Retrieved April 18, 2012. 〈http://www.cadth.ca/media/pdf/Drug- Supply- Disruptions-es-18-e.pdf〉.
16. Paterson, C. 1996. The Political Economy of Competitiveness in the New World Economy: The Case of Canada Under the Progressive Conservatives, 1984-1993. MA dissertation in Political Science, University of Ottawa. Retrieved April 18, 2012. 〈http://www.ruor.uottawa.ca/en/handle/10393/10086〉.
17. Silverman, E. 2011 (March 2). "Which Drugmaker Fails Most FD A Inspections?" Pharmalot. Retrieved April 18, 2012. 〈http://www. pharmalot.com/2011/03/which-drugmaker-fails-most-fda-inspections〉.
18. Tempest, B. 2010 (April). "A Structural Change in the Global Pharmaceutical Marketplace." Journal of Generic Medicines 7(2): 113-17.